Skip to Content
MilliporeSigma
All Photos(4)

Key Documents

View All Documentation

E6888

Sigma-Aldrich

Enalapril maleate salt

powder, ≥98% (TLC)

Synonym(s):

(S)-N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-Ala-Pro maleate salt

Sign Into View Organizational & Contract Pricing

Select a Size

250 MG
$59.80
1 G
$171.00
5 G
$592.00

$59.80

Estimated to ship onMarch 29, 2025

Request a Bulk Order
All Photos(4)

Select a Size

Change View
250 MG
$59.80
1 G
$171.00
5 G
$592.00

About This Item

Empirical Formula (Hill Notation):
C20H28N2O5 · C4H4O4
CAS Number:
76095-16-4
Molecular Weight:
492.52
EC Number:
278-375-7
UNSPSC Code:
12352200
PubChem Substance ID:
24894639
NACRES:
NA.77

$59.80

Estimated to ship onMarch 29, 2025

Request a Bulk Order

Quality Level

100

assay

≥98% (TLC)

form

powder

color

white to off-white

solubility

methanol: ≥50 mg/mL, clear, colorless to yellow

originator

Merck & Co., Inc., Kenilworth, NJ, U.S.

SMILES string

C[C@@H](C(N1[C@H](C(O)=O)CCC1)=O)N[C@H](CC(OCC)=O)CCC2=CC=CC=C2.O=C(OO)/C=C\C(O)=O

InChI

1S/C21H30N2O5.C4H4O5/c1-3-28-19(24)14-17(12-11-16-8-5-4-6-9-16)22-15(2)20(25)23-13-7-10-18(23)21(26)27;5-3(6)1-2-4(7)9-8/h4-6,8-9,15,17-18,22H,3,7,10-14H2,1-2H3,(H,26,27);1-2,8H,(H,5,6)/b;2-1-/t15-,17-,18-;/m0./s1

InChI key

UQKQUZOIQFOJOI-KJHLASMFSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Enalapril is an angiotensin-converting enzyme inhibitor. It is used to treat heart failure and high blood pressure.[1]

Application

Enalapril maleate salt has been used:
  • to reduce albumin excretion rate (AER) and glomerular lesions[2]
  • to examine the effects of enalapril pre-treatment on myocardial injury[3]
  • to investigate its efficacious doses and schedules for mitigation of radiation lung injury[4]

Biochem/physiol Actions

A long-acting angiotensin-converting enzyme inhibitor.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361fd

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCJ7542
MKCD8689
MKCD0071
MKBR8243V
MKBR2018V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chor Ho Jo et al.
Electrolyte & blood pressure : E & BP, 18(2), 31-39 (2021-01-08)
Puromycin aminonucleoside (PA) can induce nephrotic syndrome in rats, and proteinuria is an important mediator of tubulointerstitial injury in glomerulopathy. We assumed that glomerular proteinuria may affect tubular function, such as urinary concentration, and investigated whether a urinary concentration defect
Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice
Klein J, et al.
Kidney International, 90(5), 1045-1055 (2016)
Lufei Hu et al.
PloS one, 17(1), e0261000-e0261000 (2022-01-28)
Diabetic nephropathy is associated with endothelial dysfunction and oxidative stress, in which the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling pathway is impaired. We hypothesize that sGC stimulator Compound 1 can enhance NO signaling, reduce proteinuria in a diabetic
Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation
Wang G, et al.
International Journal of Molecular Sciences, 38(5), 1463-1473 (2016)
Guang Liu et al.
American journal of physiology. Renal physiology, 319(4), F697-F711 (2020-09-01)
Praliciguat, a clinical-stage soluble guanylate cyclase (sGC) stimulator, increases cGMP via the nitric oxide-sGC pathway. Praliciguat has been shown to be renoprotective in rodent models of hypertensive nephropathy and renal fibrosis. In the present study, praliciguat alone and in combination
View All Related Papers

Articles

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service